A detailed history of Black Rock Inc. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,120,563 shares of AVIR stock, worth $29.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,120,563
Previous 9,243,306 1.33%
Holding current value
$29.6 Million
Previous $37.3 Million 19.16%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.31 - $4.04 $406,279 - $495,881
-122,743 Reduced 1.33%
9,120,563 $30.2 Million
Q1 2024

May 10, 2024

SELL
$3.09 - $4.56 $619,795 - $914,649
-200,581 Reduced 2.12%
9,243,306 $37.3 Million
Q4 2023

Feb 13, 2024

BUY
$2.8 - $3.35 $3.51 Million - $4.2 Million
1,252,385 Added 15.29%
9,443,887 $28.8 Million
Q3 2023

Nov 13, 2023

BUY
$3.0 - $3.79 $1.45 Million - $1.83 Million
482,789 Added 6.26%
8,191,502 $24.6 Million
Q2 2023

Aug 11, 2023

SELL
$3.21 - $5.06 $1.07 Million - $1.69 Million
-333,023 Reduced 4.14%
7,708,713 $28.8 Million
Q1 2023

May 12, 2023

BUY
$3.0 - $4.97 $24,492 - $40,575
8,164 Added 0.1%
8,041,736 $26.9 Million
Q4 2022

Feb 13, 2023

BUY
$4.35 - $6.17 $706,661 - $1 Million
162,451 Added 2.06%
8,033,572 $38.6 Million
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $2.55 Million - $4.07 Million
463,579 Added 6.26%
7,871,121 $44.8 Million
Q2 2022

Aug 12, 2022

BUY
$5.33 - $8.18 $4.17 Million - $6.4 Million
782,849 Added 11.82%
7,407,542 $52.6 Million
Q1 2022

May 12, 2022

BUY
$5.5 - $9.19 $4.64 Million - $7.75 Million
843,496 Added 14.59%
6,624,693 $47.8 Million
Q4 2021

Feb 10, 2022

BUY
$7.67 - $44.59 $12.6 Million - $73.3 Million
1,644,396 Added 39.75%
5,781,197 $51.7 Million
Q3 2021

Nov 09, 2021

BUY
$21.33 - $35.06 $13.8 Million - $22.6 Million
645,838 Added 18.5%
4,136,801 $145 Million
Q2 2021

Aug 11, 2021

BUY
$19.22 - $59.08 $67.1 Million - $206 Million
3,490,963 New
3,490,963 $75 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $270M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.